Pre-treatment of tumour-bearing mice with THZ1, a CDK7/CDK12/13 inhibitor, before infusion with CAR T-cells attenuated cytokine release by suppressing transcription of inflammatory genes, thus preventing the associated systemic toxicity [91]. The gene discussed is CDK12; the disease is neoplasm.